Posts in: investor (5)

Transcript: eXoZymes 1st quarter 2025 and NCTx subsidiary update
investor
Transcript: eXoZymes 1st quarter 2025 and NCTx subsidiary updateMay 14, 2025
Slack Capital: EXOZ investment report and CEO interview
heltzeninvestorpress clippingsvideo
Slack Capital: EXOZ investment report and CEO interviewMay 13, 2025
eXoZymes provides first quarter 2025 and NCTx subsidiary update at 5PM EST today
press releaseinvestor
eXoZymes provides first quarter 2025 and NCTx subsidiary update at 5PM EST todayMay 12, 2025
ARCHIVE: eXoZymes to host first quarter 2025 and subsidiary NCTx update on Monday May 12, 2025, at 5PM EST
press releaseinvestorARCHIVE
ARCHIVE: eXoZymes to host first quarter 2025 and subsidiary NCTx update on Monday May 12, 2025, at 5PM ESTMay 7, 2025
ARCHIVE: eXoZymes launches subsidiary, NCTx, to unlock a promising compound for gut and liver health
press releaseinvestornutraceuticalsmedicinescienceARCHIVE
ARCHIVE: eXoZymes launches subsidiary, NCTx, to unlock a promising compound for gut and liver healthMay 6, 2025
ARCHIVE: AI transforming biotechnology: From form with AlphaFold to function with exozymes
investorvideoscienceARCHIVE
ARCHIVE: AI transforming biotechnology: From form with AlphaFold to function with exozymesApril 28, 2025
Dr. Tyler Korman, co-founder and VP of Research at eXoZymes, is excited about the 'exozymes' cover story in GEN Biotechnology, which is freely available as an Open Access paper.
press releaseinvestorvideoscienceARCHIVEkorman
ARCHIVE: GEN Biotechnology cover story: Bringing clarity and precision to the cell-free space by introducing exozymesApril 21, 2025
ARCHIVE: Bloomberg TV: Jane King interviews co-founder and VP of Research, Dr. Tyler Korman
investorpress clippingsvideoscienceARCHIVEkorman
ARCHIVE: Bloomberg TV: Jane King interviews co-founder and VP of Research, Dr. Tyler KormanApril 15, 2025
BioClick - an enzyme engineering game-changer
press releaseinvestorscienceARCHIVEkorman
ARCHIVE: BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grantApril 10, 2025
ARCHIVE: World Bio Market Insights: eXoZymes appoints Damien Perriman as Chief Commercial Officer
investorpress clippingsARCHIVEperriman
ARCHIVE: World Bio Market Insights: eXoZymes appoints Damien Perriman as Chief Commercial OfficerApril 3, 2025
Previous page
Page 5 of 9
Next page